Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 2 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 2 of 8.)

DateHeadlineEventSource5-minTo close
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complicationsPress releasePR Newswire-0.03%-0.81%
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual MeetingPress releasePR Newswire+0.98%-0.15%
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancerPress releasePR Newswire-0.93%-1.64%
Foundayo and Zepbound now covered for millions of AmericansPress releasePR Newswire+0.93%+2.62%
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity carePress releasePR Newswire-0.15%+0.04%
Lilly to participate in Goldman Sachs 47th Annual Global Healthcare ConferencePress releasePR Newswire-0.14%-0.46%
Lilly announces three acquisitions to build infectious disease portfolioPress releasePR Newswire-0.20%-1.00%
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemiaPress releasePR Newswire-0.20%-1.00%
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual MeetingPress releasePR Newswire+0.80%+1.43%
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trialPress releasePR Newswire-0.02%+1.43%
Form 8-K ELI LILLY & Co For: May 20SEC filing · Form 8-KSEC EDGAR-0.02%+1.43%
Lilly to participate in Bernstein's 42nd Annual Strategic Decisions ConferencePress releasePR Newswire-0.31%-0.58%
Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youthPress releasePR Newswire-1.27%-1.25%
Lilly and UNICEF collaborate to give millions of children a healthier startPress releasePR Newswire-1.13%-1.06%
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantriesPress releasePR Newswire-0.26%-0.32%
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trialsPress releasePR Newswire-0.16%+1.97%
Form SD ELI LILLY & CoSEC filing · Form SDSEC EDGAR+0.02%+1.52%
The Next Generation of the GLP-1 Revolution Is Already UnderwayPress releaseGlobeNewswire+2.16%+2.34%
Form 8-K ELI LILLY & Co For: May 04SEC filing · Form 8-KSEC EDGAR-0.07%-2.63%
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facilityPress releasePR Newswire-0.53%-0.43%
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four yearsPress releasePR Newswire-0.28%+1.74%
HEALTH CANADA AUTHORIZES LILLY'S KISUNLA™ (DONANEMAB), A NEW TREATMENT FOR EARLY ALZHEIMER'S DISEASEPress releaseCanada Newswire+0.90%+0.94%
Lilly declares second-quarter 2026 dividendPress releasePR Newswire-0.00%+0.76%
PDA Releases Revised Technical Reports on Process Validation and Biologics Reprocessing to Support Manufacturing ExcellencePress releasePR Web+0.90%+0.94%
Form 10-Q ELI LILLY & Co For: Mar 31SEC filing · Form 10-QSEC EDGAR+0.01%+1.36%
Form 8-K ELI LILLY & Co For: Apr 30SEC filing · Form 8-KSEC EDGAR+0.60%+3.84%
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicinesPress releasePR Newswire+0.60%+3.84%
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia veraPress releasePR Newswire+0.98%-0.77%
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialPress releaseGlobeNewswire-0.25%-1.06%
Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapiesPress releasePR Newswire-0.06%-0.66%
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic healthPress releasePR Newswire+0.55%-0.66%
Lilly confirms date and conference call for first-quarter 2026 financial results announcementPress releasePR Newswire-0.15%-1.11%
Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLLPress releasePR Newswire-0.52%-0.90%
Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.Press releasePR Newswire+0.23%+0.91%
FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsPress releasePR Newswire-0.24%-0.43%
Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersPress releasePR Newswire+1.93%+2.94%
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesityPress releasePR Newswire+0.18%-0.07%
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitisPress releasePR Newswire+0.04%-1.98%
Form DEF 14A ELI LILLY & Co For: Mar 20SEC filing · Form DEFSEC EDGAR-0.11%-0.48%
Form DEFA14A ELI LILLY & CoSEC filing · Form DEFA14ASEC EDGAR-0.11%-0.48%
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetesPress releasePR Newswire+0.61%+0.38%
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitisPress releasePR Newswire-0.15%-0.29%
Form PRE 14A ELI LILLY & Co For: Mar 06SEC filing · Form PRESEC EDGAR-0.16%+2.18%
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patientsPress releasePR Newswire+0.13%-0.68%
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areataPress releasePR Newswire+0.88%+3.40%
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsightPress releasePR Newswire+0.88%+3.40%
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The LancetPress releasePR Newswire-0.27%-0.20%
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPenPress releasePR Newswire-0.96%+1.09%
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)Press releasePR Newswire+0.14%+0.79%
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweightPress releasePR Newswire-0.45%-1.14%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground